Outlook Therapeutics, Inc.
(NASDAQ: OTLK)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

1.530

+0.090 (+6.25%)
Range 1.440 - 1.540   (6.94%)
Open 1.430
Previous Close 1.440
Bid Price 1.500
Bid Volume 29
Ask Price 1.510
Ask Volume 13
Volume 189,576
Value -
Remark
Delayed prices. Updated at 10 May 2025 04:00.
Data powered by
View All Events
Share your investing ideas
Please login to view stock data and analysis